The Parkinsonís disease treatment market is projected to reach USD 5.69 Billion by 2022 from an estimated USD 4.24 Billion in 2017, at a CAGR of 6.1%. The major factors driving the growth of this market are Growth in the aging population and the associated increase in the prevalence of Parkinsonís disease and growing government funding and support for research
The Parkinsonís disease treatment market is fragmented in nature due to the presence of a large number of players. The key players are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), and Boehringer Ingelheim (Germany).
Expansions, acquisitions, agreements, and product launches were the key strategies followed by players in the Parkinsonís disease treatment market. Some of the leading players that adopted this strategy include Teva (Israel), AbbVie (US), Boehringer Ingelheim (Germany) Lundbeck (Denmark), Acadia (US), Sun Pharma (India), US WorldMeds (US), and Dr. Reddyís (India).
Teva is one of the key players in the Parkinsonís disease treatment market. The company focuses on organic and inorganic strategies to strengthen its position in the Parkinsonís disease treatment market. For instance, in 2015, the company entered into an agreement with Takeda pharmaceutical company to commercialize rasagiline tablets in the Japan. Moreover, the company received FDA approval for AZILECT drug to treat all stages of the Parkinsonís disease.
Boehringer Ingelheim is another major player in the Parkinsonís disease treatment market. The company mainly focuses on organic strategies to strengthen its position in the market. In 2015, The company launched a new R&D strategy for the fiscal years 2015Ė2020. The company spends USD 12.2 Billion in R&D to develop new drugs in new medicine for diseases related to oncology, central nervous system, and pulmonary disease areas.
AbbVie is a key player in the Parkinsonís disease treatment market. The company focuses on organic growth to strengthen its positon in the market. For instance, in 2015, the company launched Duopa drug for treating Parkinsonís disease. Moreover, in 2014, the company opened a new manufacturing facility in the Ireland to improve its market presence.
Other important players operating in the market include Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddyís (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India), Strides (India), 1 A Pharma (India), and Upsher-Smith (US).
Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE